Articles related to Oncology, Medical

The only effective ways to treat TEC are to stop, delay, or modify your patients’ chemotherapy dose. Supportive medications, such as topical keratolytics, wound care, and high-potency topical corticosteroids, respond differently. These medications cause a 2- to 4-week recovery period following the interruption of chemotherapy, which is a somewhat gradual improvement.

In this extensive survey, patients with hematologic malignancies who have breakthrough COVID-19 have approximately 9% reduced mortality rate than they did before vaccination. Patients who received monoclonal antibodies, either alone or in conjunction with antivirals, had superior clinical results.

We can better understand outcomes in patients with a variety of ages, ethnicities, comorbidities, and exposures by using observational data. It can be challenging or even impossible to disentangle the diverse effects of dynamic elements like vaccination rates, patient behaviors, and COVID-19 pathogenicity. Randomized controlled trials involving blood cancer patients are required to fully assess the impact of COVID-19 therapies. The impact of both bivalent vaccines and prophylactic monoclonal antibodies, as well as ways to assure equitable distribution of COVID-19 vaccines and therapies, will all be determined by future study. Some of those studies must involve people who have hematologic malignancies.

Doctors and other healthcare professionals should be better able to describe the current role of immuno-oncology (IO) in patients with hepatocellular carcinoma (HCC) and evaluate how new information on novel IO strategies may alter the approach to therapy in HCC after completing this four-chapter CME activity.

The researchers tested whether a ctDNA-guided strategy could lower the need for adjuvant chemotherapy without increasing the risk of recurrence. Recurrence-free survival at 2 years was the main efficacy end objective. Adjuvant chemotherapy usage was a significant secondary end goal.

In this trial, disease-free survival was longer with adjuvant nivolumab than with placebo in the intention-to-treat population and among patients with a PD-L1 expression level of 1% or more in patients with high-risk muscle-invasive urothelial carcinoma who had had radical surgery.